Welcome guest, Sign in


Mélanie  Bruchard

Mélanie Bruchard


Ph.D. in Life Sciences and Cellular Biology, Dijon, France, 2013

Current position

Post-doc position in Department of Cell Biology and Histology, Academisch Medisch Centrum Universiteit, Amsterdam, Netherlands

Publications (since 2013)

  1. Bruchard, M., Boidot, R., Ghiringhelli, F. and Vegran, F. (2015). Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice. Genom Data 5: 314-315.
  2. Bruchard, M., Rebé, C., Derangère, V., Togbé, D., Ryffel, B., Boidot, R., Humblin, E., Hamman, A., Chalmin, F., Berger, H., Chevriaux, A., Limagne, E., Apetoh, L., Vegran, F. and Ghiringhelli, F. (2015). The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol 16(8): 859-870.
  3. Derangère, V., Chevriaux, A., Courtaut, F., Bruchard, M., Berger, H., Chalmin, F., Causse, S. Z., Limagne, E., Végran, F., Ladoire, S., Simon, B., Boireau, W., Hichami, A., Apetoh, L., Mignot, G., Ghiringhelli, F. and Rébé, C. (2014). Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells. Cell Death Differ 21(12): 1914-1924.
  4. Végran, F., Berger, H., Boidot, R., Mignot, G., Bruchard, M., Dosset, M., Chalmin, F., Rébé, C., Dérangère, V., Ryffel, B., Kato, M., Prevost-Blondel, A., Ghiringhelli, F. and Apetoh, L. (2014). The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 15(8): 758-766.
  5. Bruchard, M. and Ghiringhelli, F. (2014). [Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets]. Bull Cancer 101(6): 605-607.
  6. Bruchard, M. and Ghiringhelli, F. (2014). [Tumor microenvironment: regulatory cells and immunosuppressive cytokines]. Med Sci (Paris) 30(4): 429-435.
  7. Ghiringhelli, F., Bruchard, M. and Apetoh, L. (2013). Immune effects of 5-fluorouracil: Ambivalence matters. Oncoimmunology 2(3): e23139.
  8. Bugaut, H., Bruchard, M., Berger, H., Derangère, V., Odoul, L., Euvrard, R., Ladoire, S., Chalmin, F., Vegran, F., Rébé, C., Apetoh, L., Ghiringhelli, F. and Mignot, G. (2013). Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One 8(6): e65181.
  9. Berger, H., Végran, F., Chikh, M., Gilardi, F., Ladoire, S., Bugaut, H., Mignot, G., Chalmin, F., Bruchard, M., Derangère, V., Chevriaux, A., Rébé, C., Ryffel, B., Pot, C., Hichami, A., Desvergne, B., Ghiringhelli, F. and Apetoh, L. (2013). SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res 73(12): 3578-3590.
  10. Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., Kanellopoulos, J., Martin, F., Rébé, C., Apetoh, L. and Ghiringhelli, F. (2013). Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1): 57-64.
  11. Hervieu, A., Rébé, C., Végran, F., Chalmin, F., Bruchard, M., Vabres, P., Apetoh, L., Ghiringhelli, F. and Mignot, G. (2013). Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol 133(2): 499-508.
Protocols by Mélanie Bruchard
  1. Proximity Ligation Assay (PLA) Protocol Using Duolink® for T Cells
  2. Liquid luminescent DNA-precipitation Assay